NSSG Chemotherapy Protocol
• Interim PET-CT scan should be performed at least 11 days after course 2B. Course 3A AVD should not be delayed whilst waiting for the result • If interim PET-CT scan was Deauville 1-3 then a contrast-enhanced CT of the neck, chest, abdomen and pelvis should be performed at the end of treatment, a PET is not usually required
Download NSSG Chemotherapy Protocol
Information
Domain:
Source:
Link to this page:
Documents from same domain
CYCLOPHOSPHAMIDE / BORTEZOMIB/ …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed of MM.11 CyBorDex- Amyloidosis Authorised by …
Cyclophosphamide priming prior to PBSC harvest
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology Oxford BMT Programme B.2.20b Page 1 of 3 May 2017 V.5.4 Cyclo prime for Myeloma PSBC Harvest Authorised by: Dr Karthik Ramasamy
ATTENUATED CYCLOPHOSPHAMIDE, THALIDOMIDE & …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed MM.9 CTD - attenuated Authorised by Myeloma lead Dr. Karthik Ramasamy July 2017
Guidelines for the Management of Hypomagnesaemia …
nssg.oxford-haematology.org.ukDepartment of Clinical Haematology H.95 Page 2 of 5 November 2015 V.1.0. Guidelines for the management of hypomagnesaemia in Adult Clinical Haematology
Oxford Myeloma Group
nssg.oxford-haematology.org.ukMM.50 VTDPACE/DTPACE Authorised by Myeloma lead Dr. Karthik Ramasamy June 2022 V. 2.0 of 10 Days Drug Dose Route Comments 1 to 4 Dexamethasone 40 mg daily Oral Continuous daily/ If PBSC harvest planned only for days 1 to 4 Thalidomide (See note below) Start 50 mg and increase up to 100 mg as tolerated Oral Nocte 1 to 4
MATRix (High dose METHOTREXATE, high dose CYTARABINE ...
nssg.oxford-haematology.org.uk- Reduce thiotepa dose to 75% - Reduce methotrexate to 2g/m2 Haematological toxicity In case if inadequate bone marrow recovery (i.e. neutrophils < 1.5x109/L and platelets < 90x109/L on the intended day of re-treatment, delay cycle until counts satisfactory. Doses of the chemotherapy
ISATUXIMAB WITH POMALIDOMIDE AND …
nssg.oxford-haematology.org.ukvolume Initial rate Absence of infusion reaction Rate increment Maximum rate First infusion 250 mL 25 mL/ hour For 60 minutes 25 mL/hour every 30 minutes 150 mL/ hour Second infusion 250 mL 50 mL/ hour For 30 minutes 50 mL/ hour for 30 minutes then increase by 100 mL/ hr every 30 minutes 200 mL/ hour Subsequent infusions
ATRA + ARSENIC TRIOXIDE
nssg.oxford-haematology.org.ukArsenic Trioxide infusion duration may be extended up to 4 hours if vasomotor reactions, e.g. flushing, tachycardia and dizziness, are observed. If patients suffer severe symptoms or hypotension then the infusion should be stopped until recovery and then recommenced at a
High dose METHOTREXATE (high grade NHL CNS …
nssg.oxford-haematology.org.ukadults receiving high-dose methotrexate chemotherapy (doses >1g/m2) - Who develop significant deterioration in renal function (>1.5x ULN and rising, or the presence of oliguria) OR - Have toxic plasma methotrexate level AND - Have been treated with all standard rescue and supportive measures AND
ESHAP and R-ESHAP
nssg.oxford-haematology.org.uk2. Record stage of disease - contrast enhanced CT scan (neck, chest, abdomen and pelvis), ... In order to eliminate the risk of transmitting infective ... After 1-2 cycles with CT or PET-CT. Lymphoma group This is a controlled document and therefore must …
Related documents
Radiation Dose and Radiation Risk - Home | Stanford …
med.stanford.eduJul 14, 2012 · • Head CT 1-2 mSv • Chest CT 5-8 mSv • Abdomen CT 5-10 mSv • Pelvis CT 3-4 mSv • Abd-Pelv CT 8-15 mSv • Chest x-ray 0.02 mSv • Abdomen x-ray 0.07 mSv • Average U.S background radiation ~ 3.6 mSv CT dose of 15mSv ~ 750 chest x-rays ~ 4 years backgr. ~ 0.15% cancer (incl. non-fatal) C. McCollough, MDCT Course 2003 San Francisco ...
Bendamustine +Rituximab (BR) for CLL
nssg.oxford-haematology.org.ukThere are other bendamustine protocols, please ensure this is the correct one for patient. TREATMENT INTENT Disease modification. PRE-ASSESSMENT 1. Ensure histology is confirmed prior to administration of chemotherapy and document in notes. 2. Record stage of disease - CT scan (neck, chest, abdomen and pelvis), presence or absence of